Alchemab Therapeutics Ltd last week signed a second collaboration with Eli Lilly worth up to $415M to license its IND ready program for ALS and other neurodegenerative diseases.
CEO Jane Osbourn OBE describes Alchemab's platform, which looks for people who are resilient to disease and then sequences them to understand why, and discusses this week's deal and the company's prior one with Lilly as well.
